Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan;33(1):258-265.
doi: 10.1111/jvim.15362. Epub 2018 Dec 6.

Viral testing of 10 cases of Theiler's disease and 37 in-contact horses in the absence of equine biologic product administration: A prospective study (2014-2018)

Joy E Tomlinson  1 , Bud C Tennant  2 , Alyssa Struzyna  3 , Dawn Mrad  4 , Nimet Browne  5 , Dorothy Whelchel  6 , Philip J Johnson  7 , Camilla Jamieson  8 , Christiane V Löhr  9 , Robert Bildfell  9 , Erica C McKenzie  10 , Melissa Laverack  11 , Randall W Renshaw  12 , Edward Dubovi  12 , Amit Kapoor  13 , Richard S Meirs  3 , Rodney Belgrave  14 , Julie Engiles  15 , Gerlinde R Van de Walle  1 , Thomas J Divers  2
Affiliations

Viral testing of 10 cases of Theiler's disease and 37 in-contact horses in the absence of equine biologic product administration: A prospective study (2014-2018)

Joy E Tomlinson et al. J Vet Intern Med. 2019 Jan.

Abstract

Background: A novel equine parvovirus (EqPV-H) was recently discovered in the equine liver with Theiler's disease.

Objectives: To determine the prevalence of EqPV-H infection in naturally occurring Theiler's disease cases and in-contact horses in the absence of historical equine biologic product administration.

Animals: Ten cases of Theiler's disease from 6 separate properties were included in the study, based on the criteria of acute onset of clinical signs of liver failure with laboratory or histopathologic findings characteristic of Theiler's disease and no history of receiving an equine biologic product within the preceding 4 months. In addition, 37 in-contact horses from 4 of the 6 properties were screened for EqPV-H infection and hepatitis.

Methods: In prospective case series, cases were diagnosed with Theiler's disease by the attending veterinarian and were tested for EqPV-H by PCR of liver or serum. In-contact horses were assessed via serum chemistry and PCR at the attending veterinarian's discretion. Hepatitis was defined as serum gamma-glutamyltransferase activity above reference interval. The association of EqPV-H with hepatitis was determined by Fisher's exact test.

Results: Nine of 10 (90%) Theiler's disease cases and 54% of tested in-contact horses were EqPV-H positive. Hepatitis was significantly associated with EqPV-H infection (P = .036).

Conclusions and clinical importance: Although further study is required to identify EqPV-H as the causative agent of Theiler's disease, EqPV-H appears strongly associated with cases of fatal Theiler's disease and subclinical hepatitis in horses in contact with those cases. The prevalence of EqPV-H infection on affected properties can be high.

Keywords: acute hepatitis; hepatic failure; hepatic insufficiency; horses; liver; serum hepatitis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Case analysis outline. The numbers of Theiler's disease and in‐contact horses and the groupings are shown in the boxes. The analyses applied are indicated in red and italics
Figure 2
Figure 2
Timing of non‐biologic product–associated cases of Theiler's disease and predicted exposure periods. Ten non‐biologic‐associated cases of Theiler's disease were diagnosed on 6 properties (properties A‐F) between January 2014 and February 2018. Each property is indicated by a different color. On 4 properties, there was follow‐up monitoring of in‐contact horses by examination, serum chemistry, and equine parvovirus‐hepatitis quantitative‐PCR. The time span during which new cases of hepatitis were identified on each farm is shown above the timeline (diamonds indicate that only 1 case occurred on that farm). In equine biologic product–associated cases, hepatitis typically occurs 4‐10 weeks after administration of an equine biologic product. Assuming a similar time frame between exposure and disease for non‐biologic‐associated cases, a predicted timeline of exposure for each farm was constructed, calculated as 10 weeks before the 1st case to 4 weeks before the last case
See this image and copyright information in PMC

References

    1. Theiler A. Acute liver‐atrophy and parenchymatous hepatitis in horses Union of South Africa. Dept. of Agriculture. 5th and 6th Repts. of the Director of Veterinary Research; 1918.
    1. Meyer K. Equine encephalomyelitis. North Am Vet. 1933;14:30‐48.
    1. Madsen D. Equine encephalomyelitis. Utah Acad Sci, Arts, Lett. 1934;11:95‐99.
    1. Guglick MA, MacAllister CG, Ely RW, Edwards WC. Hepatic disease associated with administration of tetanus antitoxin in eight horses. J Am Vet Med Assoc. 1995. Jun 1;206(11):1737‐1740. - PubMed
    1. Chandriani S, Skewes‐Cox P, Zhong W, et al. Identification of a previously undescribed divergent virus from the Flaviviridae family in an outbreak of equine serum hepatitis. Proc Natl Acad Sci USA. 2013;110(15):E1407‐E1415. - PMC - PubMed

Substances